Science

Cyclin-dependent kinases (CDKs) are central regulators of both cell-cycle progression and transcriptional control. Rather than intensifying single-node CDK4/6 blockade, SPV Therapeutics designs enantiopure, next-generation small-molecule inhibitors that enable **balanced, multi-node CDK modulation—particularly CDK4/6/9—**aligned with cancer-relevant biological dependencies.

This approach is intended to restore more durable control in treatment-resistant and hard-to-treat malignancies by addressing the integrated cell-cycle and transcriptional networks that sustain tumor proliferation and survival.

Adaptive Resistance as a Therapeutic Opportunity

Cancer does not fail CDK4/6 therapy—it adapts beyond it, revealing new biological dependencies that motivate next-generation therapeutic strategies. While first-generation CDK4/6 inhibitors have improved outcomes in select cancers, many tumors develop intrinsic or acquired resistance through adaptive rewiring of cell-cycle and transcriptional programs.

SPV Therapeutics was founded on the principle that effective cancer therapy must anticipate and address adaptive tumor biology. Our programs are designed to target disease states that emerge following CDK4/6 inhibition, where conventional approaches may lose durability.

Transformative, Tumor-Agnostic Potential

SPV’s CDK-based programs are designed to address shared cell-cycle and transcriptional dependencies across multiple tumor types, rather than being constrained by tissue of origin or a single biomarker. This tumor-agnostic strategy reflects biological features common to many aggressive and treatment-refractory cancers and is intended to support the development of broader, more durable, and more inclusive cancer control.